Hologic Inc
NASDAQ:HOLX

Watchlist Manager
Hologic Inc Logo
Hologic Inc
NASDAQ:HOLX
Watchlist
Price: 74.94 USD 0.01% Market Closed
Market Cap: 16.7B USD

Intrinsic Value

The intrinsic value of one HOLX stock under the Base Case scenario is 81.05 USD. Compared to the current market price of 74.94 USD, Hologic Inc is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HOLX Intrinsic Value
81.05 USD
Undervaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Hologic Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about HOLX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is HOLX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Hologic Inc.

Explain Valuation
Compare HOLX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Hologic’s heavy reliance on its top-tier diagnostic tests and imaging systems leaves it exposed to reimbursement rate fluctuations. If governmental or private payers reduce reimbursements for breast health procedures or molecular tests, the company’s revenue and margins could face significant pressure.

Competitors with newer and more advanced structural or molecular imaging technologies could encroach on Hologic’s market share in key areas like mammography. This threat is intensified by new entrants offering bundled solutions that undercut Hologic’s pricing, reducing its ability to capture upgrades and replacements in hospital systems.

The company’s ongoing acquisitions strategy, particularly in the surgical and aesthetics segments, may undermine its operational efficiency if integration challenges arise. Delays or cost overruns related to folding new businesses into its portfolio would erode the benefits of diversification and put profitability at risk.

Bull Theses

Hologic’s leading position in breast health and molecular diagnostics provides a strong competitive moat, especially as demand for precise cancer screenings grows globally. Its well-established distribution networks and reputable brand name help the firm maintain pricing power and customer loyalty.

The company’s focus on consumable tests and service contracts creates a resilient recurring revenue stream. As molecular assays and diagnostic reagents become increasingly critical to healthcare, Hologic stands to benefit from consistent demand regardless of economic cycles.

Hologic’s proven track record of strategic acquisitions, such as in the surgical and aesthetics segments, allows it to expand market reach beyond core women’s health products. These acquisitions bolster its pipeline and help the firm access new revenue streams, reinforcing long-term growth prospects.

Show More Less
How do you feel about HOLX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Hologic Inc

Current Assets 3.7B
Cash & Short-Term Investments 2.2B
Receivables 600.8m
Other Current Assets 864.6m
Non-Current Assets 5.3B
PP&E 559.6m
Intangibles 4.2B
Other Non-Current Assets 557.5m
Current Liabilities 977.2m
Accounts Payable 968m
Accrued Liabilities 577.7m
Other Current Liabilities -568.5m
Non-Current Liabilities 3B
Long-Term Debt 2.5B
Other Non-Current Liabilities 475.8m
Efficiency

Free Cash Flow Analysis
Hologic Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Hologic Inc

Revenue
4.1B USD
Cost of Revenue
-1.8B USD
Gross Profit
2.3B USD
Operating Expenses
-1.2B USD
Operating Income
1.1B USD
Other Expenses
-502.9m USD
Net Income
565.7m USD
Fundamental Scores

HOLX Profitability Score
Profitability Due Diligence

Hologic Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

Healthy Operating Margin
Exceptional Gross Margin
Strong 3Y Average Gross Margin
Sustainable 3Y Average Operating Margin
53/100
Profitability
Score

Hologic Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.

HOLX Solvency Score
Solvency Due Diligence

Hologic Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
High Altman Z-Score
Low D/E
Long-Term Solvency
67/100
Solvency
Score

Hologic Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HOLX Price Targets Summary
Hologic Inc

Wall Street analysts forecast HOLX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HOLX is 76.86 USD with a low forecast of 70.7 USD and a high forecast of 82.95 USD.

Lowest
Price Target
70.7 USD
6% Downside
Average
Price Target
76.86 USD
3% Upside
Highest
Price Target
82.95 USD
11% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Hologic Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for HOLX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

HOLX Insider Trading
Buy and sell transactions by insiders

HOLX News

Other Videos
What is the Intrinsic Value of one HOLX stock?

The intrinsic value of one HOLX stock under the Base Case scenario is 81.05 USD.

Is HOLX stock undervalued or overvalued?

Compared to the current market price of 74.94 USD, Hologic Inc is Undervalued by 8%.

Back to Top